We are live on ! Find out more
SWTX

SpringWorks Therapeutics

Delisted

SWTX was delisted on the 30th of June, 2025.

78 hedge funds and large institutions have $1.46B invested in SpringWorks Therapeutics in 2020 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 41 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

242% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 12

143% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 7

64% more capital invested

Capital invested by funds: $895M → $1.46B (+$569M)

13% more funds holding

Funds holding: 6978 (+9)

4.09% more ownership

Funds ownership: 76.84%80.93% (+4.1%)

17% less funds holding in top 10

Funds holding in top 10: 65 (-1)

Holders
78
Holders Change
+9
Holders Change %
+13.04%
% of All Funds
1.6%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.1%
New
17
Increased
41
Reduced
12
Closed
7
Calls
Puts
Net Calls
Net Calls Change

SWTX Hedge Fund Activity: Q2 2020 in Review

78 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q2 2020, worth a combined $1.46B — up 64% from $895M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new SWTX positions and 7 closed out — a net gain of 10 holders — while 41 added to existing stakes and 12 trimmed.

The largest buyer was BlackRock, adding an estimated $19.6M. The largest seller was BVF Inc, cutting an estimated $17.1M.

  • 78 institutional investors held SpringWorks Therapeutics (SWTX) as of Q2 2020, up from 69 in Q1 2020.
  • Funds reported $1.46B of SpringWorks Therapeutics stock for Q2 2020, up 64% quarter-over-quarter.
  • 17 funds opened new SpringWorks Therapeutics positions in Q2 2020 and 7 closed out, a net change of +10 holders.
  • The largest SpringWorks Therapeutics buyer in Q2 2020 was BlackRock, an estimated $19.6M added.
  • The largest SpringWorks Therapeutics seller in Q2 2020 was BVF Inc, an estimated $17.1M sold.

Based on aggregated 13F filings for Q2 2020.